The study goal was to assess the efficacy of combined EMMPRIN and DR5 targeted therapy for pancreatic adenocarcinoma in orthotopic mouse models using multi-modal imaging. Cytotoxicity of anti-EMMPRIN antibody and anti-DR5 antibody 
Introduction
Pancreatic cancer is a highly malignant disease and the fourth leading cause of cancer death in the United States (1) . Due to the nonspecific symptoms, pancreatic cancer is typically detected at the very late stages (2) , and therefore only 15% of patients are eligible for curable operation at diagnosis (3) . Gemcitabine is the first-line therapeutic agent for unresectable pancreatic cancer, but offers only modest benefit (4) . Radiation or erlotinib (a small molecule targeting epidermal growth factor receptor) combined with gemcitabine delivered better efficacy than gemcitabine alone (5, 6) , but the routine clinical application is not recommended because of the minimal benefit. More recently, Conroy et al reported that FOLFIRINOX (quadruple therapy with oxaliplatin, irinotecan, leucovorin, and fluorouracil) extended the patient life significantly, but the median survival time was still less than a year (7) .
A monomeric monoclonal antibody, TRA-8, specifically targets only death receptor 5 (DR5) among five TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptors (8) . TRA-8 has been considered as a promising novel drug for pancreatic cancer (9, 10) . Since DR5 is present in most cancer cells, but limited in normal cells, TRA-8 enables selective killing of cancer cells without causing severe side effects. TRA-8 induces DR5 aggregation triggering apoptosis (11) and suppressing cell proliferation (12) . Because pancreatic cancer stem cells express higher level of DR5, TRA-8 will be able to suppress pancreatic-tumor regrowth efficiently (13) . The phase I clinical trial of the humanized TRA-8, tigatuzumab, was completed, and no adverse side effects were identified (14) . A monomeric monoclonal antibody targeting extracellular matrix metalloprotease inducer (EMMPRIN) was recently developed, and a significant anti-cancer effect was demonstrated in orthotopic pancreatic-cancer murine models (15) . EMMPRIN is a membrane-bound glycoprotein expressed in pancreatic cancer with high incidence (16) .
Matrix metalloproteinases (MMPs), stimulated by EMMPRIN, are essential to degrade extracellular matrix components and thereby to invade tissue boundaries (17) (18) (19) (20) .
EMMPRIN also affects tumor neovascularization by stimulating VEGF isoforms and VEGFR-2 (21) , and therefore anti-EMMPRIN therapy is capable of suppressing tumor angiogenesis as well as cancer-cell invasion and metastasis. The anti-angiogenic effect may induce the normalization of tumor microvasculature, reducing interstitial pressure and thereby improving drug delivery, which may lead to a better treatment (22) . In fact,
we recently demonstrated that anti-EMMPRIN therapy induced a synergy when used with gemcitabine in a pancreatic cancer model (23) .
Antibody-based therapies for cancer are attractive because of minimal systemic toxicity compared with chemotherapy. Since a therapeutic antibody is specific for a target in one pathway, there is the potential for combining antibody therapies for additive or synergistic benefits. The current study targeted both DR5 and EMMPRIN to maximize the overall therapeutic effect by directly inducing cancer-cell apoptosis via the TRA-8 antibody while simultaneously suppressing tumor invasion, metastasis, and angiogenesis via the anti-EMMPRIN antibody. The efficacy of the combination approach was followed over time using multi-modal imaging. 6 concentration. After 24 hours of incubation at 37 °C in 5% CO 2 , the ATP level was determined using the ATPlite assay (Perkin-Elmer, Boston, MA). The light emission from the wells of the plates was measured using an IVIS-100 imaging system (Caliper Life Sciences, Hopkinton, MA) and quantified using the vendor software. The luminescent exposure time was 60 seconds, while binning was 8. Regions of interest (ROIs) were drawn manually around the area of each individual well in the well plate, and the intensity of light emitted from each ROI was measured. Data were normalized to light emission of an equal number of untreated cells otherwise incubated under the same conditions as the treated cells.
HYNIC Conjugation and Radiolabeling. HYNIC conjugation and radiolabeling
were conducted for a biodistribution study. A fresh 1.8 mM solution of succinimidyl 6-hydrazinonicoinate (HYNIC; courtesy of Dr. Gary Bridger, AnorMED Inc., Langley, British Columbia) in dimethylformamide was prepared. Forty picomoles was transferred to glass vials, followed by freezing at -90°C, then the solutions were vacuum-dried using Advantage Benchtop Freeze Dryer (Virtis Co. Inc., Gardiner, NY) with the shelf temperature at -75°C and trap at -90°C. A vial was reconstituted with 1.0 ml of sodium phosphate buffer [0.15 mol/L (pH 7.80)] containing 1 mg of TRA-8 (HYNIC/antibody molar ratio = 6). After a 3-hour incubation at room temperature, the mixture was transferred to Slide-A-Lyzer dialysis cassette having molecular weight cutoff of 10,000 (Pierece, Rockford, IL) and then immersed into 1,000 ml of phosphate-buffered saline (PBS; pH 7.4) overnight at 4°C. The HYNIC-modified antibody was labeled with Tc99m using SnCl 2 /tricine as the transfer ligand (26) , and the unbound Tc-99m was removed by G-25 Sephadex size exclusion chromatography.
The protein concentrations of the collected fractions were measured by Lowry assay (27) . The Tc99m-labeled TRA-8 was greater than 95%, as measured by TLC using separate strips developed with saline and methyl ethyl ketone. Variance per size (var/size) was calculated by , where Sig i is the signal intensity on the pixel i, Sig is the mean signal intensity of all pixels on the line, PDF i is the probability density function on the pixel i, and N is the total number of pixels on the line. PDF i was calculated by facilitate repeated intravenous gadoteridol injections, at 4 days prior to dosing (day 17), as described in our previous studies (28, 29) . Groups 1 and 2 were intraperitoneally injected with PBS (serving as control) and anti-EMMPRIN antibody (0.2 mg) respectively on day 21, and DCE-MRI was applied on days 21 (prior to dosing; baseline imaging) and 24. Groups 3 and 4 were intraperitoneally injected with PBS (serving as control) and anti-EMMPRIN antibody (0.2 mg), respectively, twice for a week. At 1 week after therapy initiation, groups 3 and 4 were intravenously injected with Tc-99m-TRA-8 (0.40±0.02 MBq; 2.6±0.1 μg), and biodistribution study was followed at 24 hours thereafter. Groups 5-8 were intraperitoneally injected with PBS (serving as control), anti-EMMPRIN antibody (0.2 mg, semiweekly), TRA-8 (0.1 mg, weekly), and combination, respectively, for 2 weeks, while 18 F-FDG PET/CT imaging was applied weekly. Same dosing and imaging schedules were applied for groups 9-12. All tumors of groups 5-12 were collected for Ki67 and CD31 staining at the end of the imaging study. All animals were anesthetized using isoflurane gas (1~2%) during imaging. The reference region model was employed to calculate volume transfer constant, K trans (transfer rate from plasma to the extravascular-extracellular space (EES)), and rate constant, k ep (rate parameter for transport from the EES to plasma), as described in our previous study (28) . The tumor area was segmented from the anatomical MR images using the signal-intensity difference between the ROI and background, while the intensity thresholds were determined manually. The temperature of the animal bed in the Triumph scanner was maintained to 37°C during imaging. PET images were reconstructed with maximum likelihood expectation maximization algorithm (5 iterations) in high-resolution mode. For contrast-enhanced CT imaging, 0.2 ml of iohexol was intraperitoneally injected right before PET imaging.
The voltage of X-ray tube was 75 kV p and the anode current was 0.11 mA. The axial field of view was set to 78.9 mm, while 256 projections were acquired in fly gantrymotion mode. The CT acquisition time was 1.07 minutes per each animal. The coregistration of PET and CT images was performed using ImageJ version 1.40g (National Institutes of Health, Bethesda, MD).
The tumor area was manually segmented from the co-registered contrast-enhanced CT images based on the signalintensity difference between the region of interest (ROI) and background. In PET images, the standardized uptake value (SUV) was calculated by
where C is tissue activity concentration (MBq/ml), W is animal body weight (g), and D is the administered dose (MBq). Prior to dosing, the averaged tumor SUV mean of groups 5-8 (MIA PaCa-2 model) was 1.04±0.07 g/ml, and the averaged tumor volume was 91±8 mm 3 , without statistical difference among groups, while the averaged tumor SUV mean of groups 9-12 (PANC-1 model) was 0.87±0.04 g/ml, and the averaged tumor volume was 31±2 mm 3 , without statistical difference among groups.
Histologic analyses: Ki67 and CD31 staining were performed for tumor tissues of groups 5-12, with the same procedure as reported previously (29, 31) ; no tumor cells were remained in one of the samples of the TRA-8 treated group (group 7), so only 5 samples were analyzed for group 7. Two digital microphotographs (X400) were randomly selected for each tumor slice that had undergone Ki67 or CD31 staining, 
using SPOT camera on an Olympus 1X70 microscope (Olympus Optical Co., Tokyo, Japan), interfaced with personal computer and SPOT software. The proliferating (Ki67 expressing) cells were segmented by the signal-intensity difference between the target cells and background in each photograph, while the intensity and minimum particle-size thresholds were determined manually. Then the target cells were counted, and the cell density (cell-number(N)/mm 2 ) was calculated. The cell densities of the two photographs for each tumor slide were averaged. The CD31-stained area was segmented in the same way, and the area fraction (CD31-stained area/total area), considered as endothelial-cell density, was calculated. The image analysis was performed using
ImageJ, version 1.40g (National Institute of Heath, Bethesda, MD).
Statistical analysis. One-way ANOVA (32) was carried out using SAS, version Fig. 2B) . The maximum signal intensity of Cy3-anti-EMMPRIN antibody was significantly higher when combined with Cy5.5-TRA8 than when alone (p=0.003), while the variance per size was significantly smaller in the combined treatment also (p<0.001).
Anti-EMMPRIN therapy enhanced the tumor uptake of MR contrast agent,
but not Tc-99m-TRA-8. Figure 3A shows the concentration of MR contrast (gadoteridol) of two representative mice bearing orthotopic pancreatic tumor xenografts at 0 (baseline), 5, and 40 minutes after gadoteridol injection, when the animals were untreated (control) or treated with anti-EMMPRIN antibody at 3 days prior to imaging.
The tumor boundary is indicated with the white dotted circle. Figure 3B respectively. The changes of intratumoral K trans , k ep , and C 40min values were -36±9%, -18±12%, and 153±44%, respectively, for 3 days after drug dosing, whereas those of the control group were 38±8%, 10±7%, and 14±25%, respectively, during the same time (p values were <0.001, 0.085, and 0.025, respectively). The tumor-volume change of the treated group was 22±6%, while that of the control group was 52±21% without statistical difference (p=0.316). In the biodistribution study, the %ID/g of Tc-99m-TRA-8 in tumor, blood, and tumor to blood ratio for the anti-EMMPRIN treated group were 28±5%, 17±1%, and 1.8±4 respectively, while those of the control group were 20±5%, 19±1%, and 1.1±0.3 respectively. No statistically significant differences were observed between the two groups for any of these parameters. Figure 4A shows representative contrast-enhanced CT (CE-CT), 18 
F-FDG PET/CT imaging validated the additive therapeutic efficacy of combined anti-EMMPRIN antibody and TRA-8 for pancreatic cancer.
5-8 (MIA PaCa-2 model) or groups 9-12 (PANC-1 model), respectively. The mean tumor-cell proliferations of groups 6-8 were reduced 34%, 37%, and 26% relative to the control (group 5), respectively, but the statistical significance was detected only between groups 5 and 6 (p=0.035). Similarly, the mean intratumoral endothelial cell densities of groups 6-8 were reduced 46%, 37%, and 17% relative to the control, respectively, but only that of group 6 was significantly lower (p=0.009). But, in PANC-1 tumors, the proliferation cell density was significantly suppressed by either anti-EMMPRIN therapy (p=0.044) or combination therapy (p=0.016), and the endothelial cell density was significantly reduced by any of the three treatments (p<0.05).
Discussion
The super-aggregation, or capping, of death receptors has been considered to play a pivotal role to induce cellular apoptosis; the importance of Fas capping for apoptosis induction was validated (35, 36) , and it was also demonstrated that DR5 aggregation triggered by TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) was essential to drive intracellular signals for death (37, 38) . Similarly, it was found that TRA-8 resistance resulted not from the total number of DR5 expressed on the cell membrane or TRA-8 binding affinity, but perhaps from the inefficient TRA-8/DR5
oligomerization (8) . The compact binding of Cy5.5-TRA-8 will lead to the local increase of the fluorescence signal, whereas the lack of clustering may cause the signal dispersion. This is consistent with the data presented in this study; the maximum signal intensity of Cy5. significance, which is fairly comparable with TRA-8 cytotoxicity to the two cell lines.
Therefore, this technique may be applicable for biopsy specimens of pancreatic cancer during a neoadjuvant trial, to identify potential responders to TRA-8. The clustering of Cy3-anti-EMMPRIN antibody was also observed when used together with Cy5.5-TRA-8, although it did not form the capping when used alone. This is presumably because both EMMPRIN and DR5 may be present in the same lipid raft (39); EMMPRIN might be clustered along with DR5 aggregation, which is supported by the regional consistency in the distributions of Cy5.5-TRA-8 and Cy3-anti-EMMPRIN antibody when combined.
Anti-EMMPRIN therapy increased the tumor delivery of gadoteridol, presumably by reducing intratumoral microvasculature and thereby decreasing interstitial pressure.
However, the uptake of Tc-99m-TRA-8 into tumor was not enhanced by anti-EMMPRIN therapy. This discrepancy may be caused by the difference in circulation half-lives of the two agents; the plasma half-life of TRA-8 is about 6 days (data not shown), whereas that of gadoteridol is only about 3 hours in healthy mice (24) . Therefore, although high labeled 3'-deoxy-3'-fluorothymidine (FLT) (41) , although its clinical usefulness will need to be validated using more investigations. Table   Table 1 
